Between 1966 and 1982, a triple DPT vaccine was studied in France in 1,871 infants between the ages of 3 and 5 months. The study covered tolerance and serological efficacy of two immunization schedules using 2 or 3 initial injections. Computerized analysis of the 877 complete files showed satisfactory tolerance of this association and the serological efficacy of 2 initial doses of tetanus and diphtheria vaccines. Pertussis immunization is only effective after 3 injections. The presence of maternal antibodies when the first injection is given only decreases the immune response of diphtheria vaccine.

Download full-text PDF

Source

Publication Analysis

Top Keywords

serological efficacy
8
[20 years'
4
years' diphtheria-pertussis-tetanus
4
diphtheria-pertussis-tetanus vaccine]
4
vaccine] 1966
4
1966 1982
4
1982 triple
4
triple dpt
4
dpt vaccine
4
vaccine studied
4

Similar Publications

Background/objective: , the cause of ovine enzootic abortion, is a zoonotic bacterial pathogen and one of the most infectious causes of foetal death in sheep worldwide. Although the disease can be controlled using commercial inactivated and live whole-organism vaccines, there are issues with both, particularly concerning efficacy and safety. Recently, we have described the development of a new COMC (chlamydial outer membrane complex) vaccine based on a detergent-extracted outer membrane protein preparation of the pathogen, which can be delivered in a single inoculation and is both efficacious and safe.

View Article and Find Full Text PDF

Orthohantaviruses are emerging zoonotic viruses that can infect humans via the respiratory tract. There is an unmet need for an in vivo model to study infection of different orthohantaviruses in physiologically relevant tissue and to assess the efficacy of novel pan-orthohantavirus countermeasures. Here, we describe the use of a human lung xenograft mouse model to study the permissiveness for different orthohantavirus species and to assess its utility for preclinical testing of therapeutics.

View Article and Find Full Text PDF

Different agencies have emphasized the need to evaluate current serological methods for screening patients with suspected urogenital schistosomiasis. However, there is still a lack of evidence regarding the most appropriate methods for this purpose. Here we assessed the diagnostic efficacy of a newly developed serological technique that utilizes the recombinant protein -TSP-2, applied to the urine and serum of migrants suspected of having urogenital schistosomiasis.

View Article and Find Full Text PDF

Purpose: The albumin to fibrinogen ratio (AFR), a biomarker associated with inflammatory, nutritional, and coagulation status, and the CALLY index, a biomarker combining C-reactive protein, albumin, and lymphocyte count, have been suggested to correlate with prognosis in a variety of diseases in previous studies; however, studies of these two markers in ulcerative colitis (UC) are lacking. The aim of this study was to evaluate the clinical significance of AFR and CALLY index in UC.

Methods: The study included 109 UC patients and 126 healthy controls.

View Article and Find Full Text PDF

Development and evaluation of the recombinant BP26 protein-based C-ELISA for human brucellosis diagnosis.

Front Microbiol

January 2025

Jiangsu Engineering Research Center of Biological Data Mining and Healthcare Transformation, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Introduction: Timely and accurate diagnosis is crucial for the effective treatment and prevention of brucellosis. Current serological diagnostics, primarily based on lipopolysaccharide (LPS), suffer from cross-reactivity with other Gram-negative bacteria, which limits their specificity. Periplasmic protein 26 (BP26), a highly immunogenic antigen found in , has emerged as a promising alternative for enhancing diagnostic specificity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!